drugset / Trial / NCT01849562
Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants
Phase 2
Completed
30 enrolled
Alexion Pharmaceuticals, Inc.
Achillion, a wholly owned subsidiary of Alexion · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study was to evaluate the safety, tolerability, and efficacy of 12 weeks of treatment with sovaprevir, ACH-0143102, and ribavirin (RBV) in genotype-1 (GT-1), treatment-naive, hepatitis C virus (HCV) participants.
Timeline
- Start
- 2013-04
- Primary completion
- 2013-11
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Odalasvir | Small molecule | 50 mg | — |
| Comparator | Ribavirin | Small molecule | 1000 mg | — |
| Comparator | Ribavirin | Small molecule | 1200 mg | — |
| Comparator | Sovaprevir | Small molecule | 200 mg | — |
| Comparator | Sovaprevir | Small molecule | 400 mg | — |